AirDuo RespiClick is a prescription medication used to treat asthma in patients 12 years and older. It is a single product containing 2 medications: fluticasone and salmeterol. Fluticasone belongs to a group of drugs called inhaled steroids. These work by reducing swelling in the airways. Salmeterol belongs to a class of drugs called long-acting beta-agonists (LABAs). These work by relaxing and opening air passages in the lungs, making it easier to breathe.

This medication is an oral inhalation and is typically used twice a day, in the morning and evening, about 12 hours apart.

AirDuo Respicklick is not used to relieve sudden breathing problems.

Common side effects include infection of nose and throat, thrush in the mouth or throat, and headache.

Warning: asthma-related death

Long‑acting beta2‑adrenergic agonists (LABA), such as salmeterol, one of the active ingredients in AirDuo RespiClick, increase the risk of asthma‑related death.

Therefore, when treating patients with asthma, physicians should only prescribe AirDuo RespiClick for patients not adequately controlled on a long‑term asthma control medication, such as an inhaled corticosteroid, or whose disease severity clearly warrants initiation of treatment with both an inhaled corticosteroid and a LABA. Once asthma control is achieved and maintained, assess the patient at regular intervals and step down therapy (e.g., discontinue AirDuo RespiClick) if possible without loss of asthma control and maintain the patient on a long‑term asthma control medication, such as an inhaled corticosteroid. AirDuo RespiClick is not used for patients whose asthma is adequately controlled on low‑ or medium‑dose inhaled corticosteroids.